NASDAQ : TRAX
First Tracks Biotherapeutics, Inc. — Financial statements
United States
Last price 45.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.89B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 51.10M | 39.39M | 28.76M | 20.87M |
| Research & Development | 118.48M | 139.61M | 152.34M | 90.25M |
| Operating Expenses | 169.58M | 179.01M | 181.10M | 111.12M |
| Operating Income | -169.58M | -179.01M | -181.10M | -111.12M |
| Interest & Investment Income | 9.28M | 12.94M | 17.38M | 12.31M |
| Other Non Operating Income (Expenses) | -5.00K | -23.00K | 14.00K | -2.00K |
| EBT Excluding Unusual Items | -160.30M | -166.09M | -163.71M | -98.81M |
| Pretax Income | -160.30M | -166.09M | -163.71M | -106.15M |
| Net Income | -160.30M | -166.09M | -163.71M | -106.15M |
| Net Income to Common | -160.30M | -166.09M | -163.71M | -106.15M |
| Free Cash Flow | -123.82M | -143.01M | -126.16M | -93.81M |
| EBITDA | -169.07M | -178.45M | -180.50M | -110.47M |
| D&A For EBITDA | 501.00K | 559.00K | 606.00K | 652.00K |
| EBIT | -169.58M | -179.01M | -181.10M | -111.12M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 168.02M | 238.20M | 123.08M | 35.97M |
| Short-Term Investments | 73.44M | 262.29M | 354.94M | |
| Cash & Short-Term Investments | 168.02M | 311.64M | 385.37M | 390.90M |
| Prepaid Expenses | 4.76M | 4.56M | 7.65M | |
| Total Current Assets | 177.75M | 316.40M | 389.93M | 398.56M |
| Property, Plant & Equipment | 5.39M | 13.89M | 16.23M | 18.27M |
| Long-Term Investments | 35.47M | 27.03M | ||
| Other Long-Term Assets | 256.00K | 256.00K | 256.00K | |
| Total Assets | 183.14M | 330.55M | 441.89M | 444.11M |
| Accounts Payable | 2.55M | 3.11M | 3.79M | 2.42M |
| Accrued Expenses | 7.46M | 25.83M | 30.47M | 14.02M |
| Current Portion of Leases | 2.44M | 2.08M | 1.93M | 1.78M |
| Total Current Liabilities | 12.45M | 31.02M | 36.18M | 18.22M |
| Long-Term Leases | 1.90M | 12.03M | 14.11M | 16.04M |
| Total Liabilities | 14.34M | 43.05M | 50.30M | 34.26M |
| Common Stock | 35.00K | 287.51M | 391.29M | 410.65M |
| Comprehensive Income & Other | -24.00K | 305.00K | -797.00K | |
| Shareholders' Equity | 168.80M | 287.49M | 391.60M | 409.85M |
| Total Liabilities & Equity | 183.14M | 330.55M | 441.89M | 444.11M |
| Total Debt | 4.33M | 14.11M | 16.04M | 17.81M |
| Net Cash (Debt) | 163.69M | 297.53M | 369.34M | 373.09M |
| Working Capital | 165.30M | 285.38M | 353.75M | 380.33M |
| Tangible Book Value | 168.80M | 287.49M | 391.60M | 409.85M |
| Machinery | 8.35M | 8.31M | 8.24M | 8.11M |
| Leasehold Improvements | 203.00K | 203.00K | 203.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -160.30M | -166.09M | -163.71M | -106.15M |
| Depreciation & Amortization | 1.55M | 2.42M | 2.40M | 2.38M |
| Loss (Gain) From Sale of Investments | -1.33M | -4.73M | -10.31M | -10.52M |
| Stock-Based Compensation | 36.72M | 32.30M | 26.83M | 18.39M |
| Change in Accounts Payable | 11.12M | -5.31M | 17.81M | 8.39M |
| Change in Other Net Operating Assets | -11.51M | -1.52M | 1.18M | -5.49M |
| Operating Cash Flow | -123.76M | -142.93M | -125.81M | -93.00M |
| Capital Expenditures | -55.00K | -87.00K | -358.00K | -807.00K |
| Investment in Securities | 211.79M | 228.12M | 95.76M | 145.56M |
| Investing Cash Flow | 211.74M | 228.03M | 95.40M | 144.75M |
| Issuance of Common Stock | 316.57M | 30.01M | 117.52M | |
| Other Financing Activities | -280.83M | -87.09M | ||
| Financing Cash Flow | 35.74M | 30.01M | 117.52M | -87.09M |
| Net Cash Flow | 123.72M | 115.12M | 87.11M | -35.34M |
| Free Cash Flow | -123.82M | -143.01M | -126.16M | -93.81M |
| Levered Free Cash Flow | -82.76M | -63.42M | ||
| Unlevered Free Cash Flow | -82.76M | -63.42M | ||
| Change in Working Capital | -394.00K | -6.83M | 18.99M | 2.90M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Debt / Equity Ratio | 0.03 | 0.05 | 0.04 | 0.04 |
| Net Debt / Equity Ratio | -0.97 | -1.03 | -0.94 | -0.91 |
| Net Debt / EBITDA Ratio | 0.97 | 1.67 | 2.05 | 3.38 |
| Net Debt / FCF Ratio | 1.32 | 2.08 | 2.93 | 3.98 |
| Quick Ratio | 13.91 | 10.04 | 10.65 | 21.45 |
| Current Ratio | 14.28 | 10.20 | 10.78 | 21.87 |
| Return on Equity (ROE) | -48.91% | -40.85% | ||
| Return on Assets (ROA) | -28.97% | -25.55% | ||
| Return on Capital Employed (ROCE) | -99.30% | -59.80% | -44.60% | -26.10% |